Skip to main content
Download PDF

MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells

Cancer Cell International volume 21, Article number: 213 (2021) Cite this article

Abstract

Background

Chemotherapy is one of the most common treatment options for breast cancer (BC) patients. However, about half of the BC patients are chemotherapeutic resistant. Doxorubicin (DOX) is considered as one of the first line drugs in the treatment of BC patients whose function is negatively affected by multi drug resistance. Due to the severe side effects of DOX, it is very important to diagnose the DOX resistant BC patients. Therefore, assessment of molecular mechanisms involved in DOX resistance can improve the clinical outcomes in BC patients by introducing the novel therapeutic and diagnostic molecular markers. MicroRNAs (miRNAs) as members of the non-coding RNAs family have pivotal roles in various cellular processes including cell proliferation and apoptosis. Therefore, aberrant miRNAs functions and expressions can be associated with tumor progression, metastasis, and drug resistance. Moreover, due to miRNAs stability in body fluids, they can be considered as non-invasive diagnostic markers for the DOX response in BC patients.

Main body

In the present review, we have summarized all of the miRNAs that have been reported to be associated with DOX resistance in BC for the first time in the world.

Conclusions

Since, DOX has severe side effects; it is required to distinguish the non DOX-responders from responders to improve the clinical outcomes of BC patients. This review highlights the miRNAs as pivotal regulators of DOX resistance in breast tumor cells. Moreover, the present review paves the way of introducing a non-invasive panel of prediction markers for DOX response among BC patients.

Background

Breast cancer (BC) is one of the leading causes of cancer related mortalities among females [1]. It is the most frequently occurring female malignancy which is responsible for nearly 31% of all cancers diagnosed in women. An estimated 1,200,000 newly diagnosed BC patients and 465,000 mortality are reported annually in the world [2]. BC can be classified to the various distinct histological types such as lobular, ductal, papillary, and tubular carcinomas [3]. It can be also classified according to the immuno-pathological features such as progesterone receptor (PR), HER2, and estrogen receptor (ER) expressions [4]. Triple-negative breast cancer (TNBC) accounts for almost 15–20% of all BC cases which is referred to any breast tumor lacking the expressions of ER, PR, and HER2 [5, 6]. Chemotherapy is a routine treatment option for BC, while almost half of the initially responsive tumors develop resistance to various chemotherapeutic regimens [7].

Adriamycin (ADR) or Doxorubicin (DOX) is regarded as the most effective chemotherapeutic medication used for BC treatment; however, DOX effectiveness is negatively affected by multidrug resistance in BC cells during chemotherapy [8]. About 30–50% of metastatic BC patients are responsive to the DOX treatment [9]. DOX as a topoisomerase II inhibitor suppresses tumor growth through DNA replication interfering [10]. Multidrug resistance (MDR) affects the efficacy of cancer therapy and is responsible for treatment failure, tumor progression, and recurrence in a large number of BC patients. Deregulation of drug efflux transporters such as ABCB1 and multiple resistance protein-1 (MRP1) are important factors associated with MDR. Abnormal increased DNA repair processes, drug detoxification, and aberrant expression of oncogenes and tumor suppressors, are also other driving forces behind the MDR development [11, 12]. Mechanisms of DOX resistance can be classified into: (1) up regulation of drug-resistant proteins and membrane multidrug pumps in cancer cells, and (2) disruption in cellular signaling pathways which leads to the suppression of the apoptosis induced by DOX.

MicroRNAs (miRNAs) are small non-coding RNAs with 9–22 nucleotides length serving as post-transcriptional regulators of gene expression via binding to the 3′-untranslated region (UTR) of their target mRNAs that results in mRNA degradation or translational suppression [13]. Dysregulation of various miRNAs have been reported to be associated with the tumor progression and drug resistance [14,15,16]. Inhibition of miRNA activity by competitive inhibitors including miRNA sponge or target mimic has been used to study their functions. Sponge miRNAs can bind with a non-coding transcript or 3′ UTR of target gene which are expressed by U6 or CMV promoters. Lentiviral and retroviral vectors with sponge RNAs have continuous miRNA suppression in either dividing or non-dividing cells [17]. There is not any efficient method to distinguish the non-responders from those who will respond to chemotherapy. Therefore, a reliable approach for classifying patients in order to prevent unwanted side effects of chemotherapy and optimize the treatment outcome is imperative. Regarding severe DOX side effects, it is required to clarify the molecular mechanisms involved in DOX resistance to provide novel efficient therapeutic modalities to improve the clinical outcomes of BC patients. Since, microRNAs are non-invasive and more stable factors compared with mRNAs, they can be introduced as efficient and reliable markers of DOX response in BC patients.

In the present review, we have summarized all of the miRNAs that have been reported to be associated with DOX resistance in BC for the first time in the world (Table 1). We categorized the reported miRNAs based on their targets to clarify the molecular mechanisms of miRNAs mediated DOX resistance in breast tumor cells.

Table 1 All of the miRNAs associated with Doxorubicin resistance in BC
Full size table

Main text

Developmental factors and signaling pathways

Developmental signaling pathways such as WNT and NOTCH have pivotal roles in DOX response of breast tumor cells which can be regulated by miRNAs (Fig. 1). WNT signaling is a developmental pathway triggered by interaction between WNT ligands and Frizzled (FZD) receptors that result in the activation of non-canonical and canonical cascades. WNT family of proteins consists of a variety of cysteine-rich secreted glycoproteins involved in cell proliferation, polarity, apoptosis, DNA repair, embryogenesis, and tumor progression [18,19,20]. ALDH1 + breast cancer stem cells (BCSCs) are a sub population of tumor cells with a high self-renewal and tumorigenic capacities. MiR-140-5p modulates the BCSCs through inhibiting the self-renewal factors including WNT, SOX2, and SOX9 [21]. OCT4 is also the principal transcription factor for the regulation of pluripotency and self-renewing capabilities in the embryonic stem cells [22]. WNT1 induces tumor cell cycle progression and migration via interaction with specific FZD receptors in the surface of target cells which leads to β-catenin nuclear transportation and activation [23]. It has been reported that miR-140-5p reduced BCSCs proliferation, self-renewal, and sphere-formation via WNT signaling targeting. MiR-140-5p also decreased the levels of OCT4 and ALDH1 expressions and reduced the sphere formation. Moreover, miR-140-5p sensitized BCSCs to DOX mainly through the suppression of WNT1/ABCB1 axis [24].

Fig. 1
figure 1

miRNAs are involved in DOX response (resistance or sensitivity) of breast tumor cells via regulation of WNT and NOTCH signaling pathways

Full size image

Integrin β3 belongs to the integral cell-surface receptors that mainly serves as a link between the cytoskeleton and extra cellular matrix (ECM) to regulate cell adhesion, proliferation, migration, angiogenesis, cytoskeletal organization, and tumorigenesis [25,26,27]. It also enhances the growth factor release, invasion, migration, and epithelial mesenchymal transition (EMT) process in breast tumor cells [28,29,30]. WNT/β-catenin pathway exerts its effect on intracellular signal transduction via cell surface receptors such as integrin β3. It has been shown that there was FSTL1 up regulation in TNBC samples and cell lines compared with non-TNBC samples and normal mammary epithelial cells, respectively. MiR-137 also inhibited WNT/β-catenin signaling and suppressed stemness and DOX resistance of BC cells through targeting FSTL1 [31]. Dishevelled-associated activator of morphogenesis 1 (Daam1) is involved in WNT/PCP signaling pathway through interaction with Dishevelled [32, 33]. It is associated with increased cell migration via stimulation of actin reorganization during gastrulation, filopodia formation, and female germ cells meiosis [34, 35]. It has been reported that there was a converse association between the levels of miR-613 expressions and lymph node involvement in BC patients. MiR-613 was involved in regulation of DOX sensitivity via inhibition of Daam1/RhoA pathway [36].

EMT is a biological process allows epithelial cells to lose their polarity and cell–cell adhesion to gain mesenchymal organization. It has pivotal roles in various physiological and pathological processes including embryogenesis, tissue homeostasis, and tumorigenesis [37, 38]. Tumor cells that undergo EMT, acquire stem cell-like properties correlated with malignant behavior and enhanced chemo resistance [39].

Notch signaling is one of the critical developmental pathways involved in cell differentiation, migration, and drug resistance via Notch receptors (Notch1-4) and ligands (DLL and Jagged). This signaling pathway also regulates the EMT especially in cancer stem cells (CSCs) that is a fundamental process in drug resistance and tumor relapse [18, 40, 41]. It has been reported that the miR-34a expression regulated the ADR response in BC cells through NOTCH1 targeting. There was also significant miR-34a down regulation in MCF-7/ADR cells compared with MCF-7 cells. MiR-34a significantly increased ADR sensitivity. Moreover, ADR responders had higher levels of miR-34a expressions compared with non-responders [42].

Nanog is a developmental transcription factor involved in self-renewal and differentiation of stem cells [43, 44]. It is also a critical factor for the regulation of EMT process and chemo resistance during tumor progression [45, 46]. It has been reported that there was significant miR-760 down regulation in MCF-7/DOX and DOX resistant BC tissues in comparison with MCF-7 cells and chemo sensitive tissues. MiR-760 increased DOX sensitivity in BC cells through NANOG inhibition and also reversed EMT by SNAIL down regulation and E-cadherin up regulation in MCF-7/DOX cells [47]. CSCs are a small subset of tumor cells with self-renewal, recurrence, and chemo resistance capabilities [48]. Various miRNA are implicated in the formation of BCSCs and self-renewal maintenance [49]. MiR-34c was shown to inhibit the EMT process and decrease the self-renewal capabilities of BCSCs [50]. Serine/threonine-protein kinase D1 (PRKD1) is a downstream effector of diacylglycerol and protein kinase C that mediates the function of growth factors, hormones, and neurotransmitters [51]. It is also involved in activation of NF-kB signaling, DNA synthesis, and cell cycle progression [52,53,54]. PRKD1 enhanced the self-renewal ability of BCSCs via the GSK3/β-catenin signaling pathway. MiR-34a targeted the PRKD1 and reduced breast cancer stemness through the GSK3/β-catenin signaling axis [55].

PI3K/AKT and MAPK signaling pathways

MiRNAs are involved in regulation of DOX response in BC through PI3K/AKT and MAPK signaling pathways (Fig. 2). The PI3K/AKT pathway has critical roles in regulation of cell proliferation and tumor progression. PI3K activates AKT that regulates various effectors such as CREB, p27, FOXO, and mTOR. Tyrosine kinase receptors and phosphatase and tensin homolog (PTEN) are known as the positive and negative regulators of the PI3K/AKT pathway, respectively. Glycogen Synthase Kinase 3β (GSK-3β) is a serine/threonine kinase involved in the PI3K/AKT signaling pathway [56]. It has been reported that miR-29a up regulation was associated with the p-AKT and p-GSK3β over expressions which promoted the DOX-resistance in breast tumor cells [57]. MiR-205 up regulation was significantly associated with sensitivity to TAC (docetaxol, doxorubicin plus cyclophosphamide). There were miR-205 down regulations in drug-resistant BC cell lines, however, ectopic expression of miR-205 resulted in DOX restoration and taxol sensitivity via inducing apoptosis in both of the aforementioned drug-resistant BC cells. Moreover, miR-205 suppressed the PI3K/AKT signaling by VEGFA and FGF2 down regulations which resulted in enhanced tumor cell apoptosis upon chemotherapy [58]. Another study showed that there were significant miR-202-5p up regulations in DOX resistant BC specimens and cell lines. MiR-2020-5p enhanced breast tumor cell proliferation and DOX-resistance through the PTEN/PI3K/AKT signaling pathway [59].

Fig. 2
figure 2

miRNAs have important roles in DOX response (resistance or sensitivity) of breast tumor cells via regulation of PI3K/AKT and MAPK signaling pathways

Full size image

MiR-200c is an important regulator of EMT process through suppressing the E-cadherin transcriptional repressors (ZEB1 and ZEB2) [60,61,62]. Tropomyosin receptor kinase B (TrkB) is a tyrosine kinase receptor involved in cell differentiation, proliferation, and migration that functions through activation of the PI3K/AKT and MAP kinases [63]. The AKT phosphorylation plays an important role in promoting cell survival via phosphorylating and suppressing pro-apoptotic caspases and Bad [64, 65]. Bmi1 belongs to the polycomb-group protein family involved in self-renewal maintenance and inhibition of senescence [66,67,68]. It also down regulates the p19Arf that leads to p53 degradation by MDM2 [69]. It has been reported that the miR-200c increased DOX sensitivity via TrkB and Bmi1 inhibitions in breast tumor cells [70].

PTEN is a tumor suppressor that functions as a negative regulator of the AKT pathway, tumor cell migration, and apoptosis [71, 72]. It is a dual-specificity phosphatase that dephosphorylates lipid and protein substrates. It has been reported that there were miR-132 and miR-212 up-regulations in DOX resistant BC tumors and cell lines by PTEN inhibition. The miR-132 and miR-212 up regulations were also associated with NF-κB activation [73]. The FOXO is a family of transcription factors which are the downstream targets of AKT. It has been reported that the miR-222 was correlated with DOX resistance in BC cells through regulation of PTEN/AKT/FOXO1 axis [74]. MiR-21 also regulates the DOX-sensitivity in BC cells through targeting PTEN. There was a significant miR-21 up regulation in MCF-7/DOX cells compared with parental MCF-7 cells. PTEN was significantly suppressed in MCF-7/DOX cells compared to MCF-7 cells. Down regulation of miR-21 promoted the CASP3-mediated apoptosis in MCF-7/DOX cells which may be the possible explanation for increased sensitivity of MCF-7/DOX cells to DOX following transfection of miR-21 inhibitor [75]. It has been shown that there was significant miR-93 up regulation in ductal BC tissues compared with normal margins. MiR-93 markedly increased MCF-7 proliferation and survival after DOX treatment compared with control. Multidrug resistance-related genes (MDR, MRP, and BCRP) were also significantly up regulated in the MCF-7-miR-93 mimic cells. MiR-93 regulated DOX-resistance and EMT in BC cells through targeting PTEN [76]. It has been shown that miR-200c up regulated the E-cadherin through ZEB1 suppression. It also reduced AKT phosphorylation by PTEN up regulation that resulted in increased DOX sensitivity in breast tumor cells [77].

Mitogen-activated protein kinase (MAPK) is a signaling pathway that functions via sequential activation of a MAPK module including MAPKKK, MAPKK, and MAPK. There are various MAPKs such as ERK, JNK, and p38 involving in the cell growth, metabolism, and apoptosis [78]. The p38MAPK signaling has important role in apoptosis resistance in tumor cells [79]. YWHAZ encodes the 14–3-3f as an anti-apoptotic protein through the p38MAPK signaling pathway [80]. Moreover, YWHAZ has an important role in stabilization of EGFR, HER2, PKC, and b-catenin which are involved in signaling pathways, cell proliferation, and apoptosis [81,82,83]. It has been reported that the miR-30c increased DOX sensitivity in BC cells by targeting YWHAZ. There was significant miR-30c down regulation in DOX resistant breast cell lines [84]. DUSP4 belongs to the mitogen-activated protein kinase phosphatase (MKP) family that inhibits the MAPK signaling pathway [85]. It has been reported that miR-137 up regulation attenuated the DOX resistance in BC cells. MiR-137 also suppressed the EMT of breast tumor cells by DUSP4 targeting upon DOX treatment [86].

FYN is a non-receptor tyrosine kinase involved in cell growth, apoptosis, and motility [87]. It has been shown that there was miR-381 down regulation in DOX-resistant BC cells. MiR-381 re-sensitized DOX resistant BC cells via FYN inhibition and MAPK signaling inactivation [88]. During the chemo resistance process, tumor cells are able to develop resistance mechanisms by drug efflux, inactivation of detoxification enzymes, apoptosis regulation, tumor suppressor regulation, and DNA repair induction [89,90,91]. ABCB1 is a drug efflux transporter involved in multidrug resistance by increasing the intracellular levels of anticancer drugs. It has been shown that the miR-302 cluster reversed the BC cells drug resistance through ABCB1 down regulation. The miR-302 cluster also down regulated the MEKK1 as a member of the MAPK Kinase family. Therefore, miR-302 increased DOX sensitivity in BC cells by MEKK1 targeting and ABCB1 inhibition [92].

Apoptosis, cell cycle, and DNA repair

Bcl-2 interacting mediator of cell death (Bim) is a pro-apoptotic member of Bcl-2 protein family [93]. It is a key regulator of the intrinsic apoptosis pathways which directly initiates pro-apoptotic effect and induces cell apoptosis through interacting with all pro-apoptotic members of the Bcl-2 family [94, 95]. It has been reported that there were miR-181b and miR-222 up regulations in BC patients which were associated with DOX sensitivity through Bim targeting [96, 97]. The up regulation of myeloid cell leukemia 1 (MCL-1) as a pro-survival member of the Bcl-2 family, has been reported in various malignancies and shown to be correlated with a worse prognosis [98, 99]. MCL-1 enhances tumor cell survival while inhibiting their apoptosis through disrupting the normal activity of Noxa and other pro-apoptotic members of the BCL-2 family [100]. It has been shown that there was a significant miR-193b down regulation in the MCF-7/DOX resistant cells in comparison with its parental MCF-7 cells. MiR-193b increased the DOX sensitivity via MCL-1 targeting [101].

Survivin (BIRC5) belongs to the inhibitor of apoptosis (IAP) protein family. It was initially identified as a negative regulator of apoptosis which functions through inhibiting the caspase activation; however, it is now known that the survivin has a bi functional roles in survival and cell cycle [102]. Survivin exerts its anti-apoptotic activity through blocking the CASP9 function in a complex with hepatitis B X-interacting protein (HBXIP) thereby playing a crucial role in chemo resistance. It has been reported that there were significant miR-218 down regulation in drug-resistant breast cancer cell lines. MiR-218 restored the sensitivity of drug-resistant cell lines to doxorubicin and taxol through survivin targeting and apoptosis induction [103]. External antigens induce the proliferation of CD8+ and/or CD4+ helper cells that inhibit tumor progression [104].

The programmed death-ligand 1 (PD-L1) is an immune suppressor receptor expressed in T-cell membranes that reduces the proliferation of antigen-specific T-cell in the lymph nodes and increased regulatory T cells apoptosis during immune tolerance of cancer patients [105]. PD-L1 is also involved in increased chemo resistance in BC [106, 107]. It has been reported that there were miR-3609 down regulation and PD-L1 up regulation in DOX-resistant BC cell lines compared with the sensitive cells. Therefore, miR-3609 reversed DOX resistance by PD-L1 targeting and CD8+ T cells activation in BC cells. The miR-3609 down regulation was also correlated with poor prognosis in BC patients [108]. Peptidylprolyl isomerase A (PPIA) belongs to the peptidyl-prolyl cis/trans isomerase (PPIases) family and constitutes the cytosolic binding domain of cyclosporine A as an immunosuppressive agent. PPIA has key roles in various cellular processes such as cell proliferation, migration, apoptosis, immune regulation, and protein folding [109,110,111]. It has been reported that the miR-192-5p sensitized breast tumor cells to DOX and promotes apoptosis by the PPIA and BCL-2 targeting. MiR-192-5p also induced JNK-mediated apoptosis and up regulated the pro-apoptotic proteins such as CASP9 and BAD [112]. The RFWD2 is an E3 ubiquitin ligase that promotes tumor growth through p53 degradation [113]. It has been reported that there was miR-214 down regulation in BC tissues which was associated with longer disease free survival. MiR-214 increased apoptosis and DOX sensitivity in BC cells via RFWD2 targeting [114].

The findings indicated that the DOX treatment disrupted the normal cell cycle regulation by modulating the levels of miR-449 family and even its theoretically targeted genes (CDC25A, SIRT1, GMNN, E2F1, E2F3, BCL2, CDK2, and CCNE2). MiR-449 promoted DOX sensitivity by significant inhibition of cell cycle regulators including CDK2, E2F1, and E2F3 in BC cells [115]. Various mechanisms are involved in DNA repair in mammalian cells [116].

The flap endonuclease 1 (FEN1) is a critical factor during long-patch base excision repair process [117]. FEN1 has also a pivotal role during maturation of Okazaki fragments, telomere stability, and replication fork progression [118]. YY1 is a developmental transcription factor associated with cellular differentiation and proliferation [119, 120]. It has been reported that the miR-140 inhibited BC tumor progression and reduced DOX resistance through FEN1 down regulation and BER suppression. YY1 was also shown as a suppressor of FEN1 expression through miR-140 up regulation [121]. DOX-induced DNA damage activates DNA repair machinery in tumor cells. Therefore, aberrant DNA repair processes greatly influence cancer cells’ responsiveness to chemotherapy [122, 123]. It has been reported that the miR-30c was involved in DNA repair by regulation of REV1 and FANCF expressions. MiR-30c also promoted DOX-sensitivity in p53-mutant BC cells. DOX chemo resistance in p53-mutant BC cells was correlated with the miR-30c/FANCF/REV1-associated DNA damage response [124].

Transporters

ATP-binding cassette (ABC) family of transporters are drug efflux pumps involved in tumor cells MDR [125, 126]. Multidrug resistance protein 1 (MRP1) belongs to the superfamily of ABC transporters and is encoded by the ABCC1 gene. ABCC1 is correlated with the DOX resistance in MDR cancer cells [127, 128]. It has been observed that there was miR-134 down regulation in DOX-resistant breast tumor cells. MiR-134 significantly inhibited the cell proliferation and induced apoptosis in MCF-7/DOX cells via ABCC1 targeting [129]. Long non-coding RNAs (LncRNAs) are a class of non-coding RNAs (> 200 nucleotides length) with pivotal roles in tumor progression and chemo resistance [130]. It has been shown that there were linc00518 and ABCC1 up regulations in BC tissues and cell line. DOX-resistant MCF-7 cells (MCF-7/DOX) had also increased expression levels of linc00518 and ABCC1 compared to parental MCF-7 cell line. Linc00518 promoted MDR via regulating the miR-199a/ABCC1 axis in BC cells [131]. Another study has been reported that the miR-145 sensitized BC cells to DOX via ABCC1 targeting [132].

MiR-200 family is an essential regulator of EMT process which exerts its inhibitory function on tumor cell migration and invasion through down regulating E-cadherin transcriptional repressors such as ZEB1 and ZEB2 [133, 134]. It has been reported that there was a correlation between miR-200c down regulation and a poorer response of BC patients to neoadjuvant chemotherapy. Increased sensitivity of BC to epirubicin following transfection of miR-200c mimic was achieved at least in part via the inhibitory effect of miR-200c on ABCB1 expression. There were significant different levels of miR-200c expression between clinical responders and non-responders. DOX-resistant cells had significantly increased ABCB1 and decreased miR-200c levels compared with parental MCF-7 cells [135]. Another study also showed that the miR-451 increased DOX sensitivity of BC cells via ABCB1 targeting [136]. It has been reported that the miR-124-3p up regulation and ABCC4 inhibition increased DOX sensitivity in BC cells. There were significant correlations between tumor size, stage, and ABCC4 up regulation. ABCC4 down regulation inhibited the cell proliferation and migration, and induced DOX sensitivity. The miR-124-3p up regulation also significantly suppressed ABCB1 expression in MCF-7-DOX cells [137].

Uncoupling proteins (UCPs) are three structurally similar mitochondrial inner membrane transporters (UCP1/2/3) belong to the mitochondrial anion transporters family [138]. UCP-2 has a ubiquitous tissue expression and is implicated in cellular energy expenditures, mitochondrial ROS regulation, and ATP synthesis [139,140,141,142]. It has been reported that the miR-133a reduced DOX resistance in BC cells via UCP-2 targeting [143].

TGF-β and JAK/STAT signaling pathways

Transforming growth factor beta (TGFβ) signaling is a pivotal pathway involved in cell growth, cell differentiation, and apoptosis. This pathway is triggered by TGFβ ligands and receptors, which activates and translocates the SMAD proteins into the nucleus where they functions as transcription factors. SMAD4 is a mediator of TGF-β signaling pathway involved in the MDR of different tumors [144, 145]. It has been reported that there was significant miR-574 up regulation in Dox-resistant MCF-7 cells in comparison with parental cells. There were also increased levels of miR-574 in blood samples of advanced BC patients following chemotherapy. MiR-574 induced DOX resistance in BC cells through SMAD4 targeting [146]. SMAD3 is essential for the TGF-β-induced EMT and mediates the mammary epithelial cells invasion [147]. It has been reported that there was a significant miR-489 down regulation in DOX-resistant BC cells. MiR-489/SMAD3 axis regulated the DOX-resistance of breast tumor cells via EMT process [148]. PBLD is a negative regulator of TGF-β1-induced EMT during tumor progression [149]. It has been reported that there was significant reduced levels of circKDM4C expressions in BC samples which was inversely correlated with chemo resistance through the miR-548p regulation. There was also a significant direct association between circKDM4C expression and overall survival. CircKDM4C reduced the BC progression and DOX-resistance via miR-548p sponging and PBLD activating [150].

BCSCs are a sub population of tumor cancers mainly associated with tumor relapse, chemo resistance, and poor prognosis [151]. Therefore, elimination of BCSCs seems to be effective for the solving of clinical issues like drug resistance and tumor recurrence [152]. STAT family of transcription factors regulates the multiple cellular processes. Hypoxia-inducible factor-1 (HIF-1) is the main transcription factor implicated in cellular response to hypoxia. It also regulates the different genes associated with tumor aggressiveness [153]. HIF-1 signaling is critical for the activation of NOTCH pathway that affects the EMT process [154]. It has been reported that the miR-124 was involved in DOX-resistance of BCSCs via STAT3/HIF-1 signaling pathway. DOX-resistant BCSCs showed increased levels of STAT3. STAT3 up regulated the ALDH1, OCT4, and SOX2. MiR-124 reduced the DOX-resistance in BCSCs through modulation of STAT3/HIF-1 signaling pathway [155]. Role of miRNAs in regulation of DOX response in BC through TGFb and JAK/STAT signaling pathways is illustrated in Fig. 3.

Fig. 3
figure 3

Roles of miRNAs in regulation of DOX response (resistance or sensitivity) in breast tumor cells through TGFb and JAK/STAT signaling pathways

Full size image

Enzymes and structural proteins

Osteopontin (OPN) is a hydrophilic non-collagenous phosphorylated glycoprotein which is present in ECM and mediates the multiple biological functions. OPN is recognized as secreted (sOPN) or intracellular (iOPN) proteins [156]. Secreted OPN functions via interaction with the cell surface receptors including the integrin and CD44 families [157]. OPN has key roles in the diverse pathophysiological processes such as immune-mediated and inflammatory diseases as well as tissue and bone remodeling [158, 159] and is also implicated in tumor progression, metastasis, and angiogenesis [160]. It has been reported that there was a significant miR-181c down regulation in BC cells. MiR-181c suppressed the breast tumor cell proliferation and invasion while promoted DOX sensitivity. There was an inverse correlation between the miR-181c and OPN expression levels which was associated with the DOX response, metastasis, and BC patients’ overall and disease-free survival. Moreover, miR-181c inhibited the EMT of BC cells via vimentin and N-cadherin down regulations and E-cadherin up regulation [161].

Anterior gradient 2 (AGR2) belongs to the protein disulfide isomerases (PDIs) family which plays an important role in mammary epithelial proliferation, lobuloalveolar development, and protein folding [162, 163]. AGR2 up regulation early in tumorigenesis or in response to anti-hormone treatment is associated with intrinsic or acquired resistance to therapies in ER-positive breast cancers, respectively [164]. DOX-resistant BC cells were observed to have AGR2 over expression. Up regulated and down regulated AGR2 were correlated with increased and reduced DOX-sensitivity, respectively. It was also found that miR-135b-5p enhanced the DOX-sensitivity of BC cells through AGR2 targeting. MiR-135b-5p/AGR2 axis was suggested as an important pathway responsible for DOX-sensitivity in BC cells [165].

Nicotinamide phosphoribosyl transferase (NAMPT) as an important factor involved in NAD synthesis has pivotal roles in the immune response and metabolism [166, 167]. NAD is a substrate for the sirtuin deacetylase in transcriptional regulation of other genes [168]. NAMPT also promotes BC cell proliferation through stimulation of ER activity [169]. Moreover, NAMPT up regulation can be associated with DOX resistance in BC patients [170]. It has been reported that there was significant miR-154 down regulation in BC cell lines compared with normal mammary cells. There was an inverse association between the NAMPT and miR-154 expressions in BC cells. MiR-154 sensitized the BC cells to DOX through NAMPT targeting [171]. Stathmin1 (STMN1) is a microtubule-destabilizing factor involved in the regulation of cytoskeleton and microtubule dynamics [172]. STMN1 enhances the microtubule depolymerization via sequestering free tubulins [173, 174]. MiR-770 was significantly down regulated in chemo-resistant BC tissues. It also increased the DOX-sensitivity through STMN1 targeting [175].

Conclusions

DOX is one of the common first line chemotherapeutic drugs used for BC treatment; however there is a high ratio of DOX resistance among the BC patients. Since, DOX has severe side effects; it is required to distinguish the non DOX-responders from responders and also clarify the molecular mechanisms involved in DOX resistance to provide novel efficient therapeutic modalities to improve the clinical outcomes of BC patients. MiRNAs are important factors involved in drug resistance through regulation of drug efflux, DNA repair, cell cycle, and signaling pathways. They are also non-invasive and more stable factors compared with mRNAs. This review highlights the miRNAs as pivotal regulators of DOX resistance in breast tumor cells. Moreover, present review paves the way of introducing a non-invasive panel of prediction markers for DOX response among BC patients.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

BC:

Breast cancer

DOX:

Doxorubicin

miRNAs:

MicroRNAs

PR:

Progesterone receptor

ER:

Estrogen receptor

TNBC:

Triple-negative breast cancer

ADR:

Adriamycin

MDR:

Multidrug resistance

MRP1:

Multiple resistance protein-1

UTR:

Untranslated region

BCSCs:

Breast cancer stem cells

FZD:

Frizzled

ECM:

Extra cellular matrix

EMT:

Epithelial mesenchymal transition

Daam1:

Dishevelled-associated activator of morphogenesis 1

CSCs:

Cancer stem cells

PRKD1:

Protein kinase D1

PTEN:

Phosphatase and tensin homolog

GSK-3β:

Glycogen Synthase Kinase 3β

TrkB:

Tropomyosin receptor kinase B

MAPK:

Mitogen-activated protein kinase

MKP:

Mitogen-activated protein kinase phosphatase

Bim:

Bcl-2 interacting mediator of cell death

MCL-1:

Myeloid cell leukemia 1

IAP:

Inhibitor of apoptosis

HBXIP:

Hepatitis B X-interacting protein

PD-L1:

Programmed death-ligand 1

PPIA:

Peptidylprolyl isomerase A

PPIases:

Peptidyl-prolyl cis/trans isomerase

ABC:

ATP-binding cassette

MRP1:

Multidrug resistance protein 1

LncRNAs:

Long non-coding RNAs

UCPs:

Uncoupling proteins

TGFβ:

Transforming growth factor beta

HIF-1:

Hypoxia-inducible factor-1

OPN:

Osteopontin

sOPN:

Secreted Osteopontin

iOPN:

Intracellular Osteopontin

AGR2:

Anterior gradient 2

PDIs:

Protein disulfide isomerases

NAMPT:

Nicotinamide phosphoribosyl transferase

STMN1:

Stathmin1

References

  1. F Bray J Ferlay I Soerjomataram RL Siegel LA Torre A Jemal 2018 Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 68 6 394 424

    PubMed  Google Scholar 

  2. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer statistics CA Cancer J Clin. 59 4 225 49

    PubMed  Google Scholar 

  3. B Weigelt JS Reis-Filho 2009 Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 6 12 718

    CAS  PubMed  Google Scholar 

  4. T Sørlie CM Perou R Tibshirani T Aas S Geisler H Johnsen 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci 98 19 10869 74

    PubMed  PubMed Central  Google Scholar 

  5. G Bianchini JM Balko IA Mayer ME Sanders LJ Gianni 2016 Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease Nat Rev Clin Oncol 13 11 674

    CAS  PubMed  PubMed Central  Google Scholar 

  6. C Anders LAJO Carey 2008 Understanding and treating triple-negative breast cancer. 22 11 1233

    Google Scholar 

  7. L O’Driscoll MJC Clynes 2006 Biomarkers and multiple drug resistance in breast cancer Current Cancer Drug Targets 6 5 365 84

    PubMed  Google Scholar 

  8. E Austreid PE Lonning HPJE Eikesdal 2014 The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy Exp Opin Pharmacother 15 5 681 700

    CAS  Google Scholar 

  9. SM Ali H Harvey AJCO Lipton Research R 2003 Metastatic breast cancer: overview of treatment Clin Orthopaedics Relat Res 415 S132 S137

    Google Scholar 

  10. S Loi N Sirtaine F Piette R Salgado G Viale F Eenoo Van 2013 Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98 J Clin Oncol 31 7 860 7

    CAS  PubMed  Google Scholar 

  11. D Naci M-A Azreq El N Chetoui L Lauden F Sigaux D Charron 2012 α2β1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK) J Biol Chem 287 21 17065 76

    CAS  PubMed  PubMed Central  Google Scholar 

  12. AJ Lee D Endesfelder AJ Rowan A Walther NJ Birkbak PA Futreal 2011 Chromosomal instability confers intrinsic multidrug resistance Can Res 71 5 1858 70

    CAS  Google Scholar 

  13. J Lu G Getz EA Miska E Alvarez-Saavedra J Lamb D Peck 2005 MicroRNA expression profiles classify human cancers Nature. 435 7043 834 8

    CAS  PubMed  Google Scholar 

  14. Y Liang D Ridzon L Wong CJ Chen 2007 Characterization of microRNA expression profiles in normal human tissues BMC Genomics 8 1 166

    PubMed  PubMed Central  Google Scholar 

  15. AJ Lowery N Miller A Devaney RE McNeill PA Davoren C Lemetre 2009 MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neureceptor status in breast cancer Breast Cancer Res 11 3 R27

    PubMed  PubMed Central  Google Scholar 

  16. H Dvinge A Git S Gräf M Salmon-Divon C Curtis A Sottoriva 2013 The shaping and functional consequences of the microRNA landscape in breast cancer Nature 497 7449 378 82

    CAS  PubMed  Google Scholar 

  17. MS Ebert PA Sharp 2010 Emerging roles for natural microRNA sponges Curr Biol. 20 19 R858 61

    CAS  PubMed  PubMed Central  Google Scholar 

  18. MR Abbaszadegan A Riahi MM Forghanifard M Moghbeli 2018 WNT and NOTCH signaling pathways as activators for epidermal growth factor receptor in esophageal squamous cell carcinoma Cell Mol Biol Lett. 23 42

    PubMed  PubMed Central  Google Scholar 

  19. M Moghbeli MR Abbaszadegan E Golmakani MM Forghanifard 2016 Correlation of Wnt and NOTCH pathways in esophageal squamous cell carcinoma J Cell Commun Signal 10 2 129 35

    PubMed  PubMed Central  Google Scholar 

  20. M Moghbeli A Sadrizadeh MM Forghanifard HM Mozaffari E Golmakani MR Abbaszadegan 2016 Role of Msi1 and PYGO2 in esophageal squamous cell carcinoma depth of invasion J Cell Commun Signal 10 1 49 53

    PubMed  Google Scholar 

  21. B Wolfson G Eades QJWJ Zhou 2014 Roles of microRNA-140 in stem cell-associated early stage breast cancer World J Stem Cells 6 5 591

    PubMed  PubMed Central  Google Scholar 

  22. MY Lee HW Lim SH Lee HJJ Han 2009 Smad, PI3K/Akt, and Wnt-dependent signaling pathways are involved in BMP-4-induced ESC self-renewal Stem Cells 27 8 1858 68

    CAS  PubMed  Google Scholar 

  23. N Prakash WJND Wurst 2007 A Wnt signal regulates stem cell fate and differentiation in vivo Neurodegener Dis 4 4 333 8

    CAS  PubMed  Google Scholar 

  24. D Wu J Zhang Y Lu S Bo L Li L Wang 2019 miR-140–5p inhibits the proliferation and enhances the efficacy of doxorubicin to breast cancer stem cells by targeting Wnt1 Cancer Gene Ther 26 3 74 82

    CAS  PubMed  Google Scholar 

  25. M Barczyk S Carracedo DJC Gullberg research t 2010 Integrins Cell Tissue Res 339 1 269

    CAS  PubMed  Google Scholar 

  26. ROJ Hynes 2002 Integrins: bidirectional, allosteric signaling machines Cell 110 6 673 87

    CAS  PubMed  Google Scholar 

  27. HM Sheldrake LHJC Patterson 2009 Function and antagonism of β Curr Cancer Drug Targets 9 4 519 40

    CAS  PubMed  Google Scholar 

  28. AJ Galliher WPJB Schiemann 2006 β 3 integrin and Src facilitate transforming growth factor-β mediated induction of epithelial-mesenchymal transition in mammary epithelial cells Breast Cancer Res 8 4 R42

    PubMed  PubMed Central  Google Scholar 

  29. S Takayama S Ishii T Ikeda S Masamura M Doi MJ Kitajima 2005 The relationship between bone metastasis from human breast cancer and integrin αvβ3 expression Anticancer Res 25 1A 79 83

    CAS  PubMed  Google Scholar 

  30. R Wang ZQ Li X Han BL Li XY Mi LM Sun 2010 Integrin β3 and its ligand regulate the expression of uPA through p38 MAPK in breast cancer APMIS 118 12 909 17

    CAS  PubMed  Google Scholar 

  31. S Cheng Y Huang C Lou Y He Y Zhang QJC Zhang 2019 FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation Cancer Biol Ther 20 3 328 37

    CAS  PubMed  Google Scholar 

  32. R Habas Y Kato X He 2001 Wnt/Frizzled activation of Rho regulates vertebrate gastrulation and requires a novel Formin homology protein Daam1 Cell 107 7 843 54

    CAS  PubMed  Google Scholar 

  33. Y Zhu Y Tian J Du Z Hu L Yang J Liu 2012 Dvl2-dependent activation of Daam1 and RhoA regulates Wnt5a-induced breast cancer cell migration PLoS ONE 7 5 e37823

    CAS  PubMed  PubMed Central  Google Scholar 

  34. R Jaiswal D Breitsprecher A Collins IR Correa Jr MQ Xu BL Goode 2013 The formin Daam1 and fascin directly collaborate to promote filopodia formation Curr Biol 23 14 1373 9

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Y Lu Y Zhang MH Pan NH Kim SC Sun XS Cui 2017 Daam1 regulates fascin for actin assembly in mouse oocyte meiosis Cell Cycle 16 14 1350 6

    CAS  PubMed  PubMed Central  Google Scholar 

  36. H Xiong T Yan W Zhang F Shi X Jiang X Wang 2018 miR-613 inhibits cell migration and invasion by downregulating Daam1 in triple-negative breast cancer Cell Signal 44 33 42

    CAS  PubMed  Google Scholar 

  37. S Kotiyal SJB Bhattacharya communications br 2014 Breast cancer stem cells, EMT and therapeutic targets Biochem Biophys Res Commun 453 1 112 6

    CAS  PubMed  Google Scholar 

  38. T Shibue RAJN Weinberg 2017 EMT, CSCs, and drug resistance: the mechanistic link and clinical implications Nat Rev Clin Oncol 14 10 611

    PubMed  PubMed Central  Google Scholar 

  39. A Mitra L Mishra SJO Li 2015 EMT, CTCs and CSCs in tumor relapse and drug-resistance Oncotarget 6 13 10697

    PubMed  PubMed Central  Google Scholar 

  40. M Moghbeli MM Forghanifard A Sadrizadeh HM Mozaffari E Golmakani MR Abbaszadegan 2015 Role of Msi1 and MAML1 in regulation of notch signaling pathway in patients with esophageal squamous cell carcinoma J Gastrointest Cancer. 46 4 365 9

    CAS  PubMed  Google Scholar 

  41. M Moghbeli H Mosannen Mozaffari B Memar MM Forghanifard M Gholamin MR Abbaszadegan 2019 Role of MAML1 in targeted therapy against the esophageal cancer stem cells J Transl Med. 17 1 126

    PubMed  PubMed Central  Google Scholar 

  42. XJ Li MH Ji SL Zhong QB Zha JJ Xu JH Zhao 2012 MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1 Arch Med Res. 43 7 514 21

    CAS  PubMed  Google Scholar 

  43. EE Kohler CE Cowan I Chatterjee AB Malik KK Wary 2011 NANOG induction of fetal liver kinase-1 (FLK1) transcription regulates endothelial cell proliferation and angiogenesis Blood. 117 5 1761 9

    CAS  PubMed  PubMed Central  Google Scholar 

  44. MT Lee AR Bonneau CM Takacs AA Bazzini KR DiVito ES Fleming 2013 Nanog, Pou5f1 and SoxB1 activate zygotic gene expression during the maternal-to-zygotic transition Nature. 503 7476 360 4

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Y Ding AQ Yu CL Li J Fang Y Zeng DS Li 2014 TALEN-mediated Nanog disruption results in less invasiveness, more chemosensitivity and reversal of EMT in Hela cells Oncotarget. 5 18 8393 401

    PubMed  PubMed Central  Google Scholar 

  46. LE Iv Santaliz-Ruiz X Xie M Old TN Teknos Q Pan 2014 Emerging role of nanog in tumorigenesis and cancer stem cells Int J Cancer. 135 12 2741 8

    CAS  PubMed  Google Scholar 

  47. SH Hu CH Wang ZJ Huang F Liu CW Xu XL Li 2016 miR-760 mediates chemoresistance through inhibition of epithelial mesenchymal transition in breast cancer cells Eur Rev Med Pharmacol Sci. 20 23 5002 8

    PubMed  Google Scholar 

  48. EY Park E Chang EJ Lee H-W Lee H-G Kang K-H Chun 2014 Targeting of miR34a–NOTCH1 axis reduced breast cancer stemness and chemoresistance Can Res 74 24 7573 82

    CAS  Google Scholar 

  49. D Schwarzenbacher M Balic M Pichler 2013 The role of microRNAs in breast cancer stem cells Int J Mol Sci 14 7 14712 14723

    PubMed  PubMed Central  Google Scholar 

  50. F Yu Y Jiao Y Zhu Y Wang J Zhu X Cui 2012 MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells J Biol Chem 287 1 465 73

    CAS  PubMed  Google Scholar 

  51. Y Fu CSJE Rubin 2011 Protein kinase D: coupling extracellular stimuli to the regulation of cell physiology EMBO Rep 12 8 785 796

    CAS  PubMed  PubMed Central  Google Scholar 

  52. P Storz AJTE Toker 2003 Protein kinase D mediates a stress-induced NF-κB activation and survival pathway EMBO J 22 1 109 120

    CAS  PubMed  PubMed Central  Google Scholar 

  53. J Sinnett-Smith E Zhukova N Hsieh X Jiang EJJ Rozengurt 2004 Protein kinase D potentiates DNA synthesis induced by Gq-coupled receptors by increasing the duration of ERK signaling in swiss 3T3 cells J Biol Chem 279 16 16883 93

    CAS  PubMed  Google Scholar 

  54. KB Harikumar AB Kunnumakkara N Ochi Z Tong A Deorukhkar B Sung 2010 A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo Mol Cancer Ther 9 5 1136 1146

    CAS  PubMed  PubMed Central  Google Scholar 

  55. DY Kim EY Park E Chang H-G Kang Y Koo EJ Lee 2016 A novel miR-34a target, protein kinase D1, stimulates cancer stemness and drug resistance through GSK3/β-catenin signaling in breast cancer Oncotarget 7 12 14791

    PubMed Central  Google Scholar 

  56. X Zhang S Zhong Y Xu D Yu T Ma L Chen 2016 MicroRNA-3646 contributes to docetaxel resistance in human breast cancer cells by GSK-3β/β-catenin signaling pathway PLoS ONE 11 4 e0153194

    PubMed  PubMed Central  Google Scholar 

  57. H Shen L Li S Yang D Wang S Zhong J Zhao 2016 MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway Gene 593 1 84 90

    CAS  PubMed  Google Scholar 

  58. Y Hu Y Qiu E Yagüe W Ji J Liu JJC Zhang 2016 miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer Cell Death Dis 7 6 e2291

    CAS  PubMed  PubMed Central  Google Scholar 

  59. T Liu J Guo XJC Zhang 2019 MiR-202–5p/PTEN mediates doxorubicin-resistance of breast cancer cells via PI3K/Akt signaling pathway Cancer Biol Ther 20 7 989 998

    CAS  PubMed  PubMed Central  Google Scholar 

  60. PA Gregory AG Bert EL Paterson SC Barry A Tsykin G Farshid 2008 The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 Nat Cell Biol 10 5 593 601

    CAS  PubMed  Google Scholar 

  61. GJ Hurteau JA Carlson SD Spivack GJJC Brock 2007 Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin Can Re 67 17 7972 6

    CAS  Google Scholar 

  62. S-M Park AB Gaur E Lengyel MEJG Peter 2008 The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2 Genes Dev 22 7 894 907

    CAS  PubMed  PubMed Central  Google Scholar 

  63. RA Segal 2003 Selectivity in neurotrophin signaling: theme and variations Annu Rev Neurosci 26 1 299 330

    CAS  PubMed  Google Scholar 

  64. DA Altomare JRJO Testa 2005 Perturbations of the AKT signaling pathway in human cancer Oncogene 24 50 7455 7464

    CAS  PubMed  Google Scholar 

  65. D Kim JJJ Chung M Biology 2002 Akt: versatile mediator of cell survival and beyond BMB Rep 35 1 106 115

    CAS  Google Scholar 

  66. J Gil D Bernard GJD Peters 2005 Role of polycomb group proteins in stem cell self-renewal and cancer DNA Cell Biol 24 2 117 25

    CAS  PubMed  Google Scholar 

  67. VK Rajasekhar MJSC Begemann 2007 Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective Stem Cells 25 10 2498 2510

    CAS  PubMed  Google Scholar 

  68. A Sparmann M Lohuizen van 2006 Polycomb silencers control cell fate, development and cancer Nat Rev Cancer 6 11 846 856

    CAS  PubMed  Google Scholar 

  69. I-K Park SJ Morrison M Clarke 2004 Bmi1, stem cells, and senescence regulation J Clin Invest 113 2 175 179

    CAS  PubMed  PubMed Central  Google Scholar 

  70. F Kopp PS Oak E Wagner AJP Roidl 2012 miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression PLoS ONE 7 11 e50469

    CAS  PubMed  PubMed Central  Google Scholar 

  71. A Carnero JM Paramio 2014 The PTEN/PI3K/AKT pathway in vivo cancer mouse models Front Oncol 4 252

    PubMed  PubMed Central  Google Scholar 

  72. Z Li L Wang W Zhang Y Fu H Zhao Y Hu 2007 Restoring E-cadherin-mediated cell–cell adhesion increases PTEN protein level and stability in human breast carcinoma cells Biochem Biophys Res Commun 363 1 165 70

    CAS  PubMed  Google Scholar 

  73. M Xie Z Fu J Cao Y Liu J Wu Q Li 2018 MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-kappaB signaling pathway in breast cancer Biomed Pharmacother. 102 286 94

    CAS  PubMed  Google Scholar 

  74. H Shen D Wang L Li S Yang X Chen S Zhou 2017 MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway Gene. 596 110 8

    CAS  PubMed  Google Scholar 

  75. Z-X Wang B-B Lu H Wang Z-X Cheng YMJA Yin 2011 MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN Arch Med Res 42 4 281 90

    CAS  PubMed  Google Scholar 

  76. S Chu G Liu P Xia G Chen F Shi T Yi 2017 miR-93 and PTEN: key regulators of doxorubicin-resistance and EMT in breast cancer Oncol Rep 38 4 2401 7

    CAS  PubMed  Google Scholar 

  77. Y Chen Y Sun L Chen X Xu X Zhang B Wang 2013 miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling Mol Med Rep 7 5 1579 84

    CAS  PubMed  Google Scholar 

  78. V Grossi A Peserico T Tezil C Simone 2014 p38alpha MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance World J Gastroenterol. 20 29 9744 58

    CAS  PubMed  PubMed Central  Google Scholar 

  79. NM Weir K Selvendiran VK Kutala L Tong S Vishwanath M Rajaram 2007 Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK Cancer Biol Ther. 6 2 178 84

    CAS  PubMed  Google Scholar 

  80. G Tzivion VS Gupta L Kaplun V Balan 2006 14-3-3 proteins as potential oncogenes Semin Cancer Biol. 16 3 203 13

    CAS  PubMed  Google Scholar 

  81. K Ando T Ozaki H Yamamoto K Furuya M Hosoda S Hayashi 2004 Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation J Biol Chem. 279 24 25549 61

    CAS  PubMed  Google Scholar 

  82. W Filipowicz SN Bhattacharyya N Sonenberg 2008 Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 9 2 102 14

    CAS  PubMed  Google Scholar 

  83. RA McPherson A Harding S Roy A Lane JF Hancock 1999 Interactions of c-Raf-1 with phosphatidylserine and 14-3-3 Oncogene. 18 26 3862 9

    CAS  PubMed  Google Scholar 

  84. Y Fang H Shen Y Cao H Li R Qin Q Chen 2014 Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells Braz J Med Biol Res. 47 1 60 9

    CAS  PubMed  PubMed Central  Google Scholar 

  85. B Groschl M Bettstetter C Giedl M Woenckhaus T Edmonston F Hofstadter 2013 Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation Int J Cancer. 132 7 1537 46

    PubMed  Google Scholar 

  86. F Du L Yu Y Wu S Wang J Yao X Zheng 2019 miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4 Cell Death Dis 10 12 1 10

    Google Scholar 

  87. YD Saito AR Jensen R Salgia EM Posadas 2010 Fyn: a novel molecular target in cancer Cancer. 116 7 1629 37

    CAS  PubMed  Google Scholar 

  88. H Mi X Wang F Wang L Li M Zhu N Wang 2018 miR-381 induces sensitivity of breast cancer cells to doxorubicin by inactivation of MAPK signaling via FYN Eur J Pharmacol. 839 66 75

    CAS  PubMed  Google Scholar 

  89. BC Baguley 2010 Multiple drug resistance mechanisms in cancer Mol Biotechnol. 46 3 308 16

    CAS  PubMed  Google Scholar 

  90. RW Johnstone AA Ruefli SW Lowe 2002 Apoptosis: a link between cancer genetics and chemotherapy Cell. 108 2 153 64

    CAS  PubMed  Google Scholar 

  91. HL Martin L Smith DC Tomlinson 2014 Multidrug-resistant breast cancer: current perspectives Breast Cancer (Dove Med Press). 6 1 13

    CAS  PubMed  PubMed Central  Google Scholar 

  92. L Zhao Y Wang L Jiang M He X Bai L Yu 2016 MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1) J Exp Clin Cancer Res. 35 25

    PubMed  PubMed Central  Google Scholar 

  93. RA Kivits C Furneaux 2013 BIM: enabling sustainability and asset management through knowledge management Sci World J https://doi.org/10.1155/2013/983721

    Article  Google Scholar 

  94. RJ Youle AJN Strasser 2008 The BCL-2 protein family: opposing activities that mediate cell death Nat Rev Mol Cell Biol 9 1 47 59

    CAS  PubMed  Google Scholar 

  95. L O'Connor A Strasser LA O'Reilly G Hausmann JM Adams S Cory 1998 Bim: a novel member of the Bcl-2 family that promotes apoptosis EMBO J 17 2 384 95

    CAS  PubMed  PubMed Central  Google Scholar 

  96. Y Zheng X Lv X Wang B Wang X Shao Y Huang 2016 MiR-181b promotes chemoresistance in breast cancer by regulating Bim expression Oncol Rep 35 2 683 90

    CAS  PubMed  Google Scholar 

  97. H Dai L-y Xu Q Qian Q-w Zhu W-x Chen 2019 MicroRNA-222 promotes drug resistance to doxorubicin in breast cancer via regulation of miR-222/bim pathway Biosci Rep 39 7 BSR20190650

    CAS  PubMed  PubMed Central  Google Scholar 

  98. L Luo T Zhang H Liu T Lv D Yuan Y Yao 2012 MiR-101 and Mcl-1 in non-small-cell lung cancer: expression profile and clinical significance Med Oncol 29 3 1681 6

    CAS  PubMed  Google Scholar 

  99. T Zhang C Zhao L Luo H Zhao J Cheng FJ Xu 2012 The expression of Mcl-1 in human cervical cancer and its clinical significance Med Oncol 29 3 1985 91

    CAS  PubMed  Google Scholar 

  100. P Geserick J Wang M Feoktistova MJ Leverkus 2014 The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin Cell Death Dis 5 9 e1412

    CAS  PubMed  PubMed Central  Google Scholar 

  101. J Long Z Ji K Jiang Z Wang GJB Meng 2015 miR-193b modulates resistance to doxorubicin in human breast cancer cells by downregulating MCL-1 BioMed Res Int https://doi.org/10.1155/2015/373574

    Article  PubMed  PubMed Central  Google Scholar 

  102. F Li G Ambrosini EY Chu J Plescia S Tognin PC Marchisio 1998 Control of apoptosis and mitotic spindle checkpoint by survivin Nature 396 6711 580 584

    CAS  PubMed  Google Scholar 

  103. Y Hu K Xu EJB Yagüe 2015 miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer Breast Cancer Res Treat 151 2 269 80

    CAS  PubMed  Google Scholar 

  104. Y Shi JE Evans KL Rock 2003 Molecular identification of a danger signal that alerts the immune system to dying cells Nature. 425 6957 516 21

    CAS  PubMed  Google Scholar 

  105. DS Chen BA Irving FS Hodi 2012 Molecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1 Clin Cancer Res. 18 24 6580 7

    CAS  PubMed  Google Scholar 

  106. ED Carosella G Ploussard J LeMaoult F Desgrandchamps 2015 A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G Eur Urol. 68 2 267 79

    CAS  PubMed  Google Scholar 

  107. A Goodman SP Patel R Kurzrock 2017 PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas Nat Rev Clin Oncol. 14 4 203 20

    CAS  PubMed  Google Scholar 

  108. D Li X Wang M Yang Q Kan Z Duan 2019 miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint Exp Cell Res. 380 1 20 8

    CAS  PubMed  Google Scholar 

  109. H Yang M Li H Chai S Yan P Lin AB Lumsden 2005 Effects of cyclophilin A on cell proliferation and gene expressions in human vascular smooth muscle cells and endothelial cells1 J Surg Res 123 2 312 9

    CAS  PubMed  Google Scholar 

  110. S-H Kim SM Lessner Y Sakurai ZS Galis 2004 Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction Am J Pathol 164 5 1567 74

    CAS  PubMed  PubMed Central  Google Scholar 

  111. J Colgan M Asmal M Neagu B Yu J Schneidkraut Y Lee 2004 Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline-directed conformational switch in Itk Immunity 21 2 189 201

    CAS  PubMed  Google Scholar 

  112. Y Zhang Y He LL Lu ZY Zhou NB Wan GP Li 2019 miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A Kaohsiung J Med Sci 35 1 17 23

    PubMed  Google Scholar 

  113. D Dornan I Wertz H Shimizu D Arnott GD Frantz P Dowd 2004 The ubiquitin ligase COP1 is a critical negative regulator of p53 Nature. 429 6987 86 92

    CAS  PubMed  Google Scholar 

  114. J Zhang B Su C Gong Q Xi T Chao 2016 miR-214 promotes apoptosis and sensitizes breast cancer cells to doxorubicin by targeting the RFWD2-p53 cascade Biochem Biophys Res Commun. 478 1 337 42

    CAS  PubMed  Google Scholar 

  115. E Tormo S Ballester A Adam-Artigues O Burgués E Alonso B Bermejo 2019 The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors Sci Rep 9 1 1 14

    CAS  Google Scholar 

  116. MJ O'Connor 2015 Targeting the DNA damage response in cancer Mol Cell. 60 4 547 60

    CAS  PubMed  Google Scholar 

  117. L Zheng J Jia LD Finger Z Guo C Zer B Shen 2011 Functional regulation of FEN1 nuclease and its link to cancer Nucleic Acids Res. 39 3 781 94

    CAS  PubMed  Google Scholar 

  118. L Balakrishnan RA Bambara 2013 Flap endonuclease 1 Annu Rev Biochem. 82 119 38

    CAS  PubMed  PubMed Central  Google Scholar 

  119. S Gordon G Akopyan H Garban B Bonavida 2006 Transcription factor YY1: structure, function, and therapeutic implications in cancer biology Oncogene. 25 8 1125 42

    CAS  PubMed  Google Scholar 

  120. CC Wang MF Tsai TM Hong GC Chang CY Chen WM Yang 2005 The transcriptional factor YY1 upregulates the novel invasion suppressor HLJ1 expression and inhibits cancer cell invasion Oncogene. 24 25 4081 93

    CAS  PubMed  Google Scholar 

  121. X Lu R Liu M Wang AK Kumar F Pan L He 2020 MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer Oncogene. 39 1 234 47

    CAS  PubMed  Google Scholar 

  122. SP Pitroda R Bao J Andrade RR Weichselbaum PP Connell 2017 Low Recombination Proficiency Score (RPS) predicts heightened sensitivity to DNA-damaging chemotherapy in breast cancer Clin Cancer Res 23 15 4493 4500

    CAS  PubMed  PubMed Central  Google Scholar 

  123. N Kuptsova-Clarkson CB Ambrosone J Weiss MR Baer LE Sucheston G Zirpoli 2010 XPD DNA nucleotide excision repair gene polymorphisms associated with DNA repair deficiency predict better treatment outcomes in secondary acute myeloid leukemia Int J Mol Epidemiol Genet 1 4 278

    CAS  PubMed  PubMed Central  Google Scholar 

  124. S Lin L Yu X Song J Bi L Jiang Y Wang 2019 Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response Cell Death Dis 10 9 1 15

    Google Scholar 

  125. RG Deeley C Westlake SPJP Cole 2006 Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins Physiol Rev 86 3 849 899

    CAS  PubMed  Google Scholar 

  126. V Fodale M Pierobon L Liotta EJC Petricoin 2011 Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J 17 2 89

    CAS  PubMed  PubMed Central  Google Scholar 

  127. E Bonhoure D Pchejetski N Aouali H Morjani T Levade T Kohama 2006 Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting shingosine kinase-1 Leukemia 20 1 95 102

    CAS  PubMed  Google Scholar 

  128. A Angelini G Ciofani G Baccante C Febbo Di C Ilio Di F Cuccurullo 2007 Modulatory effects of heparin on cellular accumulation and cytotoxicity of doxorubicin in MRP1-overexpressing HL60/doxo cells Anticancer Res 27 1A 351 5

    CAS  PubMed  Google Scholar 

  129. L Lu F Ju H Zhao XJ Ma 2015 MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1 Biotech Lett 37 12 2387 94

    CAS  Google Scholar 

  130. M Majidinia BJD Yousefi 2016 Long non-coding RNAs in cancer drug resistance development DNA Repair 45 25 33

    CAS  PubMed  Google Scholar 

  131. L Chang Z Hu Z Zhou HJ Zhang 2018 Linc00518 contributes to multidrug resistance through regulating the MiR-199a/MRP1 axis in breast cancer Cell Physiol Biochem 48 1 16 28

    CAS  PubMed  Google Scholar 

  132. M Gao L Miao M Liu C Li C Yu H Yan 2016 miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1 Oncotarget 7 37 59714

    PubMed  PubMed Central  Google Scholar 

  133. M Korpal ES Lee G Hu YJJ Kang 2008 The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2 J Biol Chem 283 22 14910 4

    CAS  PubMed  PubMed Central  Google Scholar 

  134. H Xia SS Ng S Jiang WK Cheung J Sze X-W Bian 2010 miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion Biochem Biophys Res Commun 391 1 535 41

    CAS  PubMed  Google Scholar 

  135. J Chen W Tian H Cai H He YJ Deng 2012 Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer Med Oncol 29 4 2527 34

    CAS  PubMed  Google Scholar 

  136. O Kovalchuk J Filkowski J Meservy Y Ilnytskyy VP Tryndyak VF Chekhun 2008 Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin Mol Cancer Ther. 7 7 2152 9

    CAS  PubMed  Google Scholar 

  137. D Hu M Li J Su K Miao X Qiu 2019 Dual-targeting of miR-124-3p and ABCC4 promotes sensitivity to adriamycin in breast cancer cells Genet Test Mol Biomarkers. 23 3 156 65

    CAS  PubMed  Google Scholar 

  138. O Boss P Muzzin JP Giacobino 1998 The uncoupling proteins, a review Eur J Endocrinol 139 1 1 9

    CAS  PubMed  Google Scholar 

  139. MD Brand TCJC Esteves 2005 Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3 Cell Metabol 2 2 85 93

    CAS  Google Scholar 

  140. T Nübel Y Emre D Rabier B Chadefaux D Ricquier FJ Bouillaud 2008 Modified glutamine catabolism in macrophages of Ucp2 knock-out mice Biochim Biophys Acta 1777 1 48 54

    PubMed  Google Scholar 

  141. MC Saleh MB Wheeler CBJJ Chan 2006 Endogenous islet uncoupling protein-2 expression and loss of glucose homeostasis in ob/ob mice J Endocrinol 190 3 659 67

    CAS  PubMed  Google Scholar 

  142. JF Turrens 2003 Mitochondrial formation of reactive oxygen species J Physiol 552 2 335 344

    CAS  PubMed  PubMed Central  Google Scholar 

  143. Y Yuan YF Yao SN Hu J Gao L Zhang 2015 MiR-133a is functionally involved in doxorubicin-resistance in breast cancer cells MCF-7 via its regulation of the expression of uncoupling protein 2 PLoS ONE 10 6 e0129843

    PubMed  PubMed Central  Google Scholar 

  144. SU Moon MH Kang JH Sung JW Kim JO Lee YJ Kim 2015 Effect of Smad3/4 on chemotherapeutic drug sensitivity in colorectal cancer cells Oncol Rep. 33 1 185 92

    CAS  PubMed  Google Scholar 

  145. CL Roland LF Starker Y Kang D Chatterjee J Estrella A Rashid 2017 Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection Surgery. 161 3 753 9

    PubMed  Google Scholar 

  146. FD Sun PC Wang RL Luan SH Zou X Du 2018 MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells Eur Rev Med Pharmacol Sci. 22 5 1342 50

    PubMed  Google Scholar 

  147. EA Kohn Z Du M Sato CM Schyndle Van MA Welsh Y-A Yang 2010 A novel approach for the generation of genetically modified mammary epithelial cell cultures yields new insights into TGFβ signaling in the mammary gland Breast Cancer Res 12 5 1 16

    Google Scholar 

  148. L Jiang D He D Yang Z Chen Q Pan A Mao 2014 MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway FEBS Lett 588 11 2009 15

    CAS  PubMed  Google Scholar 

  149. DM Li J Zhang WM Li JT Cui YM Pan SQ Liu 2013 MAWBP and MAWD inhibit proliferation and invasion in gastric cancer World J Gastroenterol. 19 18 2781 92

    CAS  PubMed  PubMed Central  Google Scholar 

  150. Y Liang X Song Y Li P Su D Han T Ma 2019 circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer Oncogene. 38 42 6850 66

    CAS  PubMed  Google Scholar 

  151. D Hong AJ Fritz KH Finstad MP Fitzgerald A Weinheimer AL Viens 2018 Suppression of breast cancer stem cells and tumor growth by the RUNX1 transcription factor Mol Cancer Res 16 12 1952 64

    CAS  PubMed  PubMed Central  Google Scholar 

  152. X Bai J Ni J Beretov P Graham YJ Li 2018 Cancer stem cell in breast cancer therapeutic resistance Cancer Treat Rev 69 152 163

    CAS  PubMed  Google Scholar 

  153. EM Francesco De R Lappano MF Santolla S Marsico A Caruso MJ Maggiolini 2013 HIF-1α/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs) Breast Cancer Res 15 4 R64

    PubMed  PubMed Central  Google Scholar 

  154. EM Francesco De M Maggiolini AMJI Musti 2018 Crosstalk between Notch, HIF-1α and GPER in breast cancer EMT Int J Mol Sci 19 7 2011

    PubMed Central  Google Scholar 

  155. C Liu H Xing C Guo Z Yang Y Wang YJCC Wang 2019 MiR-124 reversed the doxorubicin resistance of breast cancer stem cells through STAT3/HIF-1 signaling pathways Cell Cycle 18 18 2215 27

    CAS  PubMed  PubMed Central  Google Scholar 

  156. M Inoue MLJI Shinohara 2011 Intracellular osteopontin (iOPN) and immunity Immunol Res 49 1–3 160 172

    CAS  PubMed  PubMed Central  Google Scholar 

  157. CA Piccirillo E Bjur I Topisirovic N Sonenberg OJN Larsson 2014 Translational control of immune responses: from transcripts to translatomes Nat Immunol 15 6 503 511

    CAS  PubMed  Google Scholar 

  158. S Rittling RJJ Singh 2015 Osteopontin in immune-mediated diseases J Dental Res 94 12 1638 1645

    CAS  Google Scholar 

  159. JW Leavenworth B Verbinnen Q Wang E Shen HJP Cantor 2015 Intracellular osteopontin regulates homeostasis and function of natural killer cells Proc Natl Acad Sci 112 2 494 499

    CAS  PubMed  Google Scholar 

  160. F Lin Y Li J Cao S Fan J Wen G Zhu 2011 Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells Mol Biol Rep 38 8 5205 10

    CAS  PubMed  Google Scholar 

  161. B Han J Huang Y Han J Hao X Wu H Song 2019 The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin Int J Biol Macromol 125 544 56

    CAS  PubMed  Google Scholar 

  162. Brychtova V, Mohtar A, Vojtesek B, Hupp TR, editors. Mechanisms of anterior gradient-2 regulation and function in cancer. Seminars in cancer biology; 2015: Elsevier.

  163. S Verma ML Salmans M Geyfman H Wang Z Yu Z Lu 2012 The estrogen-responsive Agr2 gene regulates mammary epithelial proliferation and facilitates lobuloalveolar development Dev Biol 369 2 249 60

    CAS  PubMed  PubMed Central  Google Scholar 

  164. ML Salmans F Zhao BJ Andersen 2013 The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker Breast Cancer Res 15 2 1 14

    Google Scholar 

  165. Y Zhang F Xia F Zhang Y Cui Q Wang H Liu 2019 miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2 J Exp Clin Cancer Res 38 1 26

    CAS  PubMed  PubMed Central  Google Scholar 

  166. AA Grolla C Travelli AA Genazzani JK Sethi 2016 Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine Br J Pharmacol. 173 14 2182 94

    CAS  PubMed  PubMed Central  Google Scholar 

  167. RE Shackelford K Mayhall NM Maxwell E Kandil D Coppola 2013 Nicotinamide phosphoribosyltransferase in malignancy: a review Genes Cancer. 4 11–12 447 56

    PubMed  PubMed Central  Google Scholar 

  168. A Menssen P Hydbring K Kapelle J Vervoorts J Diebold B Luscher 2012 The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop Proc Natl Acad Sci USA 109 4 E187 96

    CAS  PubMed  Google Scholar 

  169. M Zangooei M Nourbakhsh MH Ghahremani R Meshkani A Khedri A Shadboorestan 2018 Investigating the effect of visfatin on ERalpha phosphorylation (Ser118 and Ser167) and ERE-dependent transcriptional activity EXCLI J. 17 516 25

    PubMed  PubMed Central  Google Scholar 

  170. MA Folgueira DM Carraro H Brentani DF Patrao EM Barbosa MM Netto 2005 Gene expression profile associated with response to doxorubicin-based therapy in breast cancer Clin Cancer Res. 11 20 7434 43

    CAS  PubMed  Google Scholar 

  171. Z Bolandghamat Pour M Nourbakhsh K Mousavizadeh Z Madjd SS Ghorbanhosseini Z Abdolvahabi 2019 Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin BMC Cancer. 19 1 1027

    PubMed  PubMed Central  Google Scholar 

  172. T Bai T Yokobori B Altan M Ide E Mochiki M Yanai 2017 High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients Br J Cancer 116 9 1177 85

    CAS  PubMed  PubMed Central  Google Scholar 

  173. U Marklund N Larsson HM Gradin G Brattsand MJT Gullberg 1996 Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics EMBO J 15 19 5290 8

    CAS  PubMed  PubMed Central  Google Scholar 

  174. CI Rubin GFJJ Atweh 2004 The role of stathmin in the regulation of the cell cycle J Cell Biochem 93 2 242 250

    CAS  PubMed  Google Scholar 

  175. Y Li Y Liang Y Sang X Song H Zhang Y Liu 2018 MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1 Cell Death Dis 9 1 1 12

    Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Amir Sadra Zangouei & Maliheh Alimardani

  2. Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Maliheh Alimardani & Meysam Moghbeli

Authors
  1. Amir Sadra Zangouei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maliheh Alimardani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Meysam Moghbeli
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ASZ and MA were involved in search strategy and drafting. MM supervised the project and revised and edited the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Meysam Moghbeli.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zangouei, A.S., Alimardani, M. & Moghbeli, M. MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells. Cancer Cell Int 21, 213 (2021). https://doi.org/10.1186/s12935-021-01873-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12935-021-01873-4

Keywords

Cancer Cell International

ISSN: 1475-2867

Contact us